Needham Maintains Buy on NeoGenomics, Raises Price Target to $22

Benzinga Newsdesk www.benzinga.com Positive 75.8%

Neg 0% Neu 0% Pos 75.8%

Needham analyst Mike Matson maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price target from $19 to $22.

Comments

No comments yet. Be the first!